Akershus University Hospital
Lørenskog, 1478, Norway
NCT Number: NCT02864771
The purpose of this study is to identify markers of increased risk for incident ventricular arrhythmias and cardiovascular events in patients already being treated with an implantable cardioverter-defibrillator (ICD) by exploring patient history and clinical findings, biological markers, ECG markers, and echocardiographic markers.
This study is active but is not currently recruiting participants.
18 year and older
All sexes
Observational
Lørenskog, 1478, Norway
This is a multicenter prospective cohort study to assess the prognostic value of potential biomarkers for incident ventricular arrhythmias and cardiovascular events in patients with implantable cardioverter-defibrillator (ICD). In addition to information from the baseline visit and future study visits, the investigators will also register information from the patients medical records concerning comorbidities and previous medical events.
The data will be summarized with respect to demographic and baseline characteristics and risk markers/ measurements. The final diagnosis of incident cardiovascular events will be established by an adjudication committee with two senior physicians reviewing all information available on the patients, including information on the clinical outcome of the patient. The investigators will use multivariate statistical models to assess the individual performance of biomarkers/other tests.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Duration of follow-up will be a minimum of 180 days following inclusion of the final patient.
Registered from the monitoring function of the ICD
Time frame: Duration of follow-up will be a minimum of 180 days following inclusion of the final patient.
Time frame: Duration of follow-up will be a minimum of 180 days following inclusion of the final patient.
Time frame: Duration of follow-up will be a minimum of 180 days following inclusion of the final patient.
Time frame: Duration of follow-up will be a minimum of 180 days following inclusion of the final patient.
Time frame: Duration of follow-up will be a minimum of 180 days following inclusion of the final patient.
Time frame: Duration of follow-up will be a minimum of 180 days following inclusion of the final patient.
Time frame: Duration of follow-up will be a minimum of 180 days following inclusion of the final patient.
Time frame: Duration of follow-up will be a minimum of 180 days following inclusion of the final patient.
University Hospital, Akershus
Other
Scandinavian Multicenter Study to Advance Risk Stratification in Heart Disease- Ventricular Arrhythmias: A Multicenter, Observational Trial
Acronym: SMASH 1
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04394637
Ventricular Arrhythmias
Baltimore, Maryland, United States
View Trial DetailsNCT07727330
Ventricular Arrhythmias
View Trial DetailsNCT06281977
Arrhythmias, Cardiac, Cardiac Conduction System Disease
Rochester, Minnesota, United States
View Trial DetailsNCT07590908
Arrhythmias, Cardiac, Cardiac Conduction System Disease
Pavia, Italy
View Trial Details